Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 10/8/2017)


Breast Cancer

Institution Study Title  
CUHK A Study Of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine In Patients With Her2+ Metastatic Breast Cancer Who Have Received Two Or More Prior Her2-Directed Regimens In The Metastatic Setting (NALA) Closed
CUHK A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy Closed
HKU A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] Closed
PYNEH A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases [Breast Cancer Radium-223] Click for Details
QEH A Study Of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine In Patients With Her2+ Metastatic Breast Cancer Who Have Received Two Or More Prior Her2-Directed Regimens In The Metastatic Setting (NALA) Closed
QEH A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy Click for Details
QEH A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases (BAY17096) Closed
QEH A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Nab Paclitaxel Compared with Placebo with Nab Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer (WO29522) Closed
QEH A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355) [Protocol no.: MK-3475-355] Click for Details
*institution arranged in alphabetical order

For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.